Trimeris (Nasdaq: TRMS) is going to pay a $1 per share dividend to stockholders of record as of Dec. 19.

The biopharmaceutical firm paid a $33.3 million dividend earlier this year.

Trimeris, which developed and sells the HIV drug Fuzeon along with partner Roche, has been under pressure from investors to return more money to investors. Partly as a result Trimeris curtailed new product development and implemented other cost savings.

Trimeris shares trade up 84 cents at $2.84 Wednesday.